RxDoctor Payments Data

Kara Smith, MD

Neurology · Boston, MANPI 1194952523

Payments from drug & device makers

$119,905in general payments, 2019–2025

Across 20 payments — averaging $5995.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$105K
  • Acadia Pharmaceuticals Inc$13K
  • Amneal Pharmaceuticals LLC$2K
  • Medtronic$127
  • UCB, Inc.$58
  • Biogen$18
$57,000in research payments, 2019–2025

Across 6 payments — averaging $9500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acadia Pharmaceuticals Inc$57K

What the payments were for

  • Consulting fees$2,31684%
  • Food & beverage$43516%

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB SA8$105,154
Acadia Pharmaceuticals Inc5$12,824
Amneal Pharmaceuticals LLC4$1,725
Medtronic1$127
UCB, Inc.1$58
Biogen1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$119,905 in reported general payments places this provider in the 80th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$43,824
Medicare patients
214
Services billed
481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate83$411,999
IngrezzaValbenazine Tosylate25$328,149
RytaryCarbidopa/Levodopa90$231,070
GocovriAmantadine Hcl34$139,723
Austedo XrDeutetrabenazine17$99,492
NourianzIstradefylline16$47,975
NeuproRotigotine19$18,906
Carbidopa-LevodopaCarbidopa/Levodopa334$18,046
Carbidopa26$12,419
NuedextaDextromethorphan Hbr/Quinidine11$12,327
TopamaxTopiramate14$10,129
Aimovig AutoinjectorErenumab-Aooe13$8,734
Entacapone21$8,501
Carbidopa-Levodopa ErCarbidopa/Levodopa123$7,045
Rasagiline Mesylate36$5,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$12,824$411,99983 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$1,725$232,345104 claims
UCB, Inc.Neupro$58$18,90619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 761 neurology providers in Massachusetts.

Other neurology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →